The Acute Effects Of Cannabis With And Without Cannabidiol In Adults And Adolescents: A Randomised, Double‐Blind, Placebo‐Controlled, Crossover Experiment
Will Lawn,Katie Trinci,Claire Mokrysz,Anna Borissova,Shelan Ofori,Kat Petrilli,Michael Bloomfield,Zarah R. Haniff,Daniel Hall,Natalia Fernandez‐Vinson,Simiao Wang,Amir Englund,Edward Chesney,Matthew B. Wall,Tom P. Freeman,H. Valerie Curran
DOI: https://doi.org/10.1111/add.16154
2023-02-09
Addiction
Abstract:Background and aims Long‐term harms of cannabis may be exacerbated in adolescence, but little is known about the acute effects of cannabis in adolescents. We aimed to: (1) compare the acute effects of cannabis in adolescent and adult cannabis users, and (2) determine if cannabidiol (CBD) acutely modulates the effects of delta‐9‐tetrahydocannabinol (THC). Design Randomised, double‐blind, placebo‐controlled, crossover experiment. The experiment was registered on ClinicalTrials.gov (NCT04851392). Setting Laboratory in London, United Kingdom. Participants Twenty‐four adolescents (12 women, 16‐17 year‐olds) and 24 adults (12 women, 26‐29 year‐olds) who used cannabis 0.5‐3 days/week and were matched on cannabis use frequency (mean=1.5 days/week). Intervention We administered three weight‐adjusted vaporised cannabis flower preparations: 'THC' (8mg THC for 75kg person); 'THC+CBD' (8mg THC and 24mg CBD for 75kg person); and 'PLA' (matched placebo). Measurements Primary outcomes were: i) subjective 'feel drug effect'; (ii) verbal episodic memory (delayed prose recall); and (iii) psychotomimetic effect (Psychotomimetic States Inventory). Findings Compared with 'PLA', 'THC' and 'THC+CBD' significantly (p 3). There was no evidence that CBD significantly modulated the acute effects of THC. Conclusions Adolescent cannabis users are neither more resilient nor more vulnerable than adult cannabis users to the acute psychotomimetic, memory‐impairing, or subjective effects of cannabis. Furthermore, in adolescents and adults, vaporised cannabidiol does not mitigate the acute harms caused by delta‐9‐tetrahydocannabinol.
psychiatry,substance abuse